Opinion

Video

Common Adverse Reactions to EGFR Therapy

Alan Chin, PharmD, BCOP, presents an overview of the most prevalent and common adverse reactions associated with EGFR-targeted therapies in metastatic NSCLC and shares strategies to mitigate toxicities, with a focus on managing dermatologic events such as rash and itching.

  1. Provide a broad overview of common adverse effects associated with EGFR-targeted therapies in metastatic NSCLC.
  2. What proactive strategies do you recommend for preventing dermatologic toxicities, such as rash and acneiform eruptions, in patients receiving EGFR-targeted therapies?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
5 experts in this video
Related Content
X-ray image of lung cancer -- Image credit: Sebastian Kaulitzki | stock.adobe.com
December 19th 2024

FDA Approves Ensartinib for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Gillian McGovern, Assistant Editor
Site Logo
December 20th 2024

Examining the 505(b)(2) Pathway and Implementation into EHR

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Lung cancer concept | Image Credit: © Mikki Orso - stock.adobe.com
December 5th 2024

Zenocutuzumab-zbco Granted Accelerated Approval for Patients With NSCLC, Pancreatic Ductal Adenocarcinoma

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

X-ray scans of lungs -- Image credit: Dario Lo Presti | stock.adobe.com
December 5th 2024

FDA Grants Breakthrough Therapy Designation to Sac-TMT for Previously Treated NSCLC

Gillian McGovern, Assistant Editor
patient listening to doctor - Image credit: Konstantin Yuganov | stock.adobe.com
November 27th 2024

New Strategies in SCLC and DLBCL Are Transforming the Treatment Landscape

Kennedy Ferruggia, Assistant Editor